

New Categories for Medicare Advantage Part B Step Therapy

Florida Blue Medicare has updated its Part B Step Therapy programs. Effective **October 1, 2024**, two new categories and one updated category were added to the Part B Step Therapy program for BlueMedicareSM Medicare Advantage plans.

Drug Alternatives

Step Therapy is required, and the definition of medical necessity must be met, for certain non-preferred medications. We encourage you to consider prescribing one of the following preferred alternatives (prior authorization may apply) instead of the non-preferred drugs:

New Categories for Part B Step Therapy Program:

Immune Globulins

Preferred Products			Non-Preferred Products	
IVIG	Gammagard liquid	J1569	Alyglo	J1599
	Gammaked	J1561	Asceniv	J1554
	Gamunex-C	J1459	Bivigam	J1556
	Privigen	J1568	Gammagard S/D	J1566
	Octagam		Panzyga	J1576
SCIG	Cutaquig	J1551	Cuvitru	J1555
	Hizentra	J1559	Xembify	J1558
	HyQvia	J1575		

Iron Supplementation Agents

Preferred Product		Non-Preferred Products	
Feraheme	Q0138, Q0139	Injectafer	J1439
Ferumoxytol			
Ferrlecit	J2916	Monoferric	J1437
Sodium ferric gluconate C			
Infed	J1750		
Triferic	J1443, J1444, J1445		
Venofer	J1756		

Updates to Existing Part B Step Therapy Program Category:

Complement Inhibitors*

Preferred Product(s)		Indication	Non-preferred Product	
Empaveli	C9399, J3490	Paroxysmal Nocturnal Hemoglobinuria (PNH)	Soliris	J1300
Ultomiris PiaSky	J1303 J3590			
Ultomiris	J1303			

Note: Added preferred product is included in bold, red font.

*No changes to preferred/non-preferred products for other indications in Complement Inhibitor Step Therapy program.